ACE-031 (Ramatercept, ActRIIB-Fc) — Research Compounds Library | RetatrutideCompare

Soluble activin receptor IIB-Fc fusion designed to neutralize myostatin and related ligands. A phase 2 trial in Duchenne muscular dystrophy showed dose-dependent muscle mass gain but was halted in 2013 over nose/gum bleeding and telangiectasia signals.